FDA begins proceedings to remove erythromycin estolate from market.
D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D002648:Child; D004917:Erythromycin / Q000031:analogs & derivatives*; D004918:Erythromycin Estolate / Q000009:adverse effects*; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration
D004917:Erythromycin; D004918:Erythromycin Estolate